Published in J Neurosci on September 17, 2008
Calcium signaling and neurodegenerative diseases. Trends Mol Med (2009) 2.03
The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: From respiration to apoptosis. Mitochondrion (2011) 1.40
The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther (2009) 1.10
Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-beta variants in cells composing the cerebral vessel walls. FASEB J (2009) 1.08
Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. Stroke (2009) 1.08
Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet (2010) 1.06
Necrostatin-1 ameliorates symptoms in R6/2 transgenic mouse model of Huntington's disease. Cell Death Dis (2011) 1.00
N-acetyl-serotonin offers neuroprotection through inhibiting mitochondrial death pathways and autophagic activation in experimental models of ischemic injury. J Neurosci (2014) 1.00
The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci (2011) 0.96
Meclizine is neuroprotective in models of Huntington's disease. Hum Mol Genet (2010) 0.92
Delayed onset of the diurnal melatonin rise in patients with Huntington's disease. J Neurol (2009) 0.91
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci (2013) 0.88
Dipyrone inhibits neuronal cell death and diminishes hypoxic/ischemic brain injury. Neurosurgery (2011) 0.87
Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. Mol Neurobiol (2012) 0.86
The role of the immune system in triplet repeat expansion diseases. Mediators Inflamm (2015) 0.85
Calcium signaling and neurodegeneration. Acta Naturae (2010) 0.83
Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis (2013) 0.83
Neuroprotective effect of melatonin: a novel therapy against perinatal hypoxia-ischemia. Int J Mol Sci (2013) 0.82
Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease. J Bioenerg Biomembr (2010) 0.80
Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid β and the Asn23 Iowa mutation. Biochem J (2013) 0.80
The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Neurobiol Dis (2015) 0.78
Novel cell-based in vitro screen to identify small-molecule inhibitors against intracellular replication of Cryptococcus neoformans in macrophages. Int J Antimicrob Agents (2016) 0.77
Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology. Mol Neurobiol (2014) 0.75
Berbamine inhibited the growth of prostate cancer cells in vivo and in vitro via triggering intrinsic pathway of apoptosis. Prostate Cancer Prostatic Dis (2016) 0.75
Methazolamide improves neurological behavior by inhibition of neuron apoptosis in subarachnoid hemorrhage mice. Sci Rep (2016) 0.75
Data in the activities of caspases and the levels of reactive oxygen species and cytochrome c in the •OH-induced fish erythrocytes treated with alanine, citrulline, proline and their combination. Data Brief (2016) 0.75
Role of Mitochondria in Neonatal Hypoxic-Ischemic Brain Injury. J Neurosci Rehabil (2015) 0.75
Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release. Proc Natl Acad Sci U S A (2017) 0.75
Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell (1997) 24.57
The biochemistry of apoptosis. Nature (2000) 18.91
Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell (1997) 12.83
Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell (1996) 12.59
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 11.90
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 8.41
Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 7.19
Endonuclease G is an apoptotic DNase when released from mitochondria. Nature (2001) 6.20
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 4.21
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med (2000) 4.18
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A (1998) 4.14
A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A (1999) 3.96
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci (2001) 3.55
Apoptosis and caspases in neurodegenerative diseases. N Engl J Med (2003) 3.40
Mitochondria and cell death. Mechanistic aspects and methodological issues. Eur J Biochem (1999) 3.07
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology (2006) 3.01
Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature (1999) 2.97
Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol (2003) 2.57
Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A (2006) 2.07
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A (2003) 2.05
Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain (2002) 2.00
Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci (2000) 1.92
Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery (2001) 1.69
Mitochondria and neuronal death/survival signaling pathways in cerebral ischemia. Neurochem Res (2004) 1.55
A cell-based screen for drugs to treat Huntington's disease. Neurobiol Dis (2004) 1.45
The mitochondrial permeability transition pore. Biochem Soc Symp (1999) 1.43
Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death. Proc Natl Acad Sci U S A (2003) 1.40
The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx (2005) 1.33
Mitochondrial permeability transitions: how many doors to the house? Biochim Biophys Acta (2005) 1.25
Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med (2004) 1.19
Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing. J Biol Chem (2001) 1.09
Possible apoptotic mechanism in epidermal cell acantholysis induced by pemphigus vulgaris autoimmunoglobulins. Apoptosis (2004) 1.08
Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochim Biophys Acta (2005) 1.08
Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model. Neurobiol Dis (2005) 0.99
Comparative kinetic analysis reveals that inducer-specific ion release precedes the mitochondrial permeability transition. Biochim Biophys Acta (2005) 0.96
Antioxidant compounds and Ca(2+) pathway blockers differentially protect against methylmercury and mercuric chloride neurotoxicity. J Neurosci Res (2001) 0.94
Kinetic model for Ca2+-induced permeability transition in energized liver mitochondria discriminates between inhibitor mechanisms. J Biol Chem (2007) 0.92
Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays. Physiol Genomics (2002) 0.89
Protective role of Cop in Rip2/caspase-1/caspase-4-mediated HeLa cell death. Biochim Biophys Acta (2006) 0.89
Dysregulation of receptor interacting protein-2 and caspase recruitment domain only protein mediates aberrant caspase-1 activation in Huntington's disease. J Neurosci (2005) 0.88
Minocycline is protective in a mouse model of Huntington's disease. Ann Neurol (2003) 0.87
Replicative senescence enhances apoptosis induced by pemphigus autoimmune antibodies in human keratinocytes. FEBS Lett (2004) 0.86
Mitochondria, NO and neurodegeneration. Biochem Soc Symp (1999) 0.86
Antiapoptotic effect of dipyrone on HL-60, Jurkat and Raji cell lines submitted to UV irradiation, arachidonic acid and cycloheximide treatments. Int Immunopharmacol (2001) 0.79
Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease. Ann Neurol (2003) 0.79
Ischemia-induced extracellular release of serotonin plays a role in CA1 neuronal cell death in rats. Stroke (1992) 0.79
The effect of gossypol and Lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Exp Mol Pathol (1984) 0.76
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 4.21
Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol (2008) 3.48
Genomic dissection of population substructure of Han Chinese and its implication in association studies. Am J Hum Genet (2009) 2.93
The metabolomics standards initiative. Nat Biotechnol (2007) 2.54
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet (2007) 2.54
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem (2004) 2.43
Mass-spectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research. Metabolomics (2009) 2.21
Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A (2003) 2.21
Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg (2011) 2.21
Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A (2005) 2.15
A small peptide mimicking the key domain of MEPE/OF45 interacting with CHK1 protects human cells from radiation-induced killing. Cell Cycle (2010) 2.06
Biochemical evidence for Ku-independent backup pathways of NHEJ. Nucleic Acids Res (2003) 2.05
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A (2003) 2.05
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96
Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol (2005) 1.95
Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A (2003) 1.92
Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci (2002) 1.92
Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem (2005) 1.91
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.89
A genome-wide search for signals of high-altitude adaptation in Tibetans. Mol Biol Evol (2010) 1.86
Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene (2003) 1.82
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci U S A (2006) 1.82
Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease. J Clin Invest (2011) 1.79
Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A (2011) 1.76
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci (2003) 1.72
Drosophila neuroblast asymmetric divisions: cell cycle regulators, asymmetric protein localization, and tumorigenesis. J Cell Biol (2008) 1.70
Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet (2002) 1.67
Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A (2004) 1.63
Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol (2003) 1.63
Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet (2010) 1.62
Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci (2002) 1.58
Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci (2004) 1.58
Chiari I malformation as a cause of trigeminal neuralgia: case report. Neurosurgery (2008) 1.57
Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J Neurosci (2004) 1.54
Increased generation of granule cells in adult Bcl-2-overexpressing mice: a role for cell death during continued hippocampal neurogenesis. Eur J Neurosci (2005) 1.53
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood (2012) 1.51
Calcitriol restores renovascular function in estrogen-deficient rats through downregulation of cyclooxygenase-2 and the thromboxane-prostanoid receptor. Kidney Int (2013) 1.49
Mutations in TUBB8 and Human Oocyte Meiotic Arrest. N Engl J Med (2016) 1.46
The Clp1p/Flp1p phosphatase ensures completion of cytokinesis in response to minor perturbation of the cell division machinery in Schizosaccharomyces pombe. J Cell Sci (2004) 1.45
Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons. Proc Natl Acad Sci U S A (2005) 1.42
Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology (2004) 1.41
Consensus scoring criteria for improving enrichment in virtual screening. J Chem Inf Model (2005) 1.41
Philanthropy funding for neurosurgery research and program development. Neurosurgery (2013) 1.40
Fundamental role of the Rip2/caspase-1 pathway in hypoxia and ischemia-induced neuronal cell death. Proc Natl Acad Sci U S A (2003) 1.40
A genetic pathway composed of Sox14 and Mical governs severing of dendrites during pruning. Nat Neurosci (2009) 1.38
Allele-specific silencing of mutant Huntington's disease gene. J Neurochem (2009) 1.35
In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet (2010) 1.34
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood (2012) 1.33
Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J Neurochem (2004) 1.33
Metabolomic analysis and signatures in motor neuron disease. Metabolomics (2005) 1.31
Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis (2005) 1.30
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res (2013) 1.30
T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity (2010) 1.29
Red blood cell (RBC) survival determined in humans using RBCs labeled at multiple biotin densities. Transfusion (2010) 1.28
Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res (2004) 1.25
Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. J Biol Chem (2005) 1.25
Zinc irreversibly damages major enzymes of energy production and antioxidant defense prior to mitochondrial permeability transition. J Biol Chem (2007) 1.25
Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med (2011) 1.23
Lipidomics profiling by high-resolution LC-MS and high-energy collisional dissociation fragmentation: focus on characterization of mitochondrial cardiolipins and monolysocardiolipins. Anal Chem (2010) 1.23
FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Res Treat (2011) 1.22
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem (2009) 1.22
Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. J Med Chem (2011) 1.22
Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J Biol Chem (2006) 1.21
NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens. Cell Res (2012) 1.21
Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta (2006) 1.21
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem (2003) 1.20
Treatment of ruptured and unruptured cerebral aneurysms in the USA: a paradigm shift. J Neurointerv Surg (2011) 1.19
The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep (2012) 1.19
Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med (2004) 1.19
NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One (2011) 1.19
An essential role for SKAP-55 in LFA-1 clustering on T cells that cannot be substituted by SKAP-55R. J Exp Med (2005) 1.18
Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS. Mol Cell Neurosci (2002) 1.17
Huntingtin inhibits caspase-3 activation. EMBO J (2006) 1.17
Locomotion defects, together with Pins, regulates heterotrimeric G-protein signaling during Drosophila neuroblast asymmetric divisions. Genes Dev (2005) 1.15
CHK1-regulated S-phase checkpoint response reduces camptothecin cytotoxicity. Cell Cycle (2002) 1.15
An ana2/ctp/mud complex regulates spindle orientation in Drosophila neuroblasts. Dev Cell (2011) 1.13
Role of mPKCI, a novel mu-opioid receptor interactive protein, in receptor desensitization, phosphorylation, and morphine-induced analgesia. Mol Pharmacol (2004) 1.13
Zinc is a potent inhibitor of thiol oxidoreductase activity and stimulates reactive oxygen species production by lipoamide dehydrogenase. J Biol Chem (2001) 1.13